Navigation Links
Clinical Data & Innovation Will Shift PCI and CABG Procedures in Europe
Date:5/14/2009

By 2013, over 685,000 PCI and 165,000 CABG procedures will be performed, according to Millennium Research Group

WALTHAM, Mass., May 14 /PRNewswire/ -- According to two new Millennium Research Group (MRG) reports, emerging clinical data and innovations in device technology will shift the balance between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) procedures for unique subgroups with coronary artery disease through 2013. MRG's European Markets for Interventional Cardiology Devices 2009 and European Markets for Coronary Artery Bypass Graft Devices 2009 reports indicate that by 2013, over 685,000 PCI procedures and over 165,000 CABG procedures will be performed across Europe.

Results of clinical studies supporting the benefits of PCI will expand the eligible patient population to include higher-risk subgroups, which until recently have been untreated by PCI. In 2008, results of the CARDia trial identified similar rates of myocardial infarction, stroke, or death at 12 months in diabetic patients who received either PCI or CABG surgery. Initial results of the SYNTAX trial found the same trend for patients with complicated forms of CAD. Consequently, while CABG surgery will remain the gold standard treatment for complex CAD, some of these patients may now be considered eligible for PCI.

"Results of recent clinical studies demonstrate that PCI can be used to treat patients with significantly more complicated forms of CAD than previously thought possible," says Anuk Karunaratne, Senior Analyst at MRG. "Innovations in PCI technology -- such as improved stent design and intravascular ultrasound (IVUS) -- will enable treatment of more complicated cases and will allow PCI use to expand further into CABG territory, although it's unlikely that referral patterns will shift significantly in the short-term. Nevertheless, continued innovation and clinical data will influence physicians to select PCI as the optimal treatment for some higher-risk patients."

MRG's new reports, European Markets for Interventional Cardiology Devices 2009 and European Markets for Coronary Artery Bypass Graft (CABG) Devices 2009 cover France, Germany, Italy and the UK, and also provide data such as usage rates, units per procedure, average selling prices, and growth rates. Detailed market shares are provided across all market segments for key companies, including Abbott Vascular, Boston Scientific, Johnson & Johnson's Cordis, Medtronic, Sorin Group, Terumo Medical, Volcano, and more.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through syndicated reports, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... Kenneth Cochran, DSc, RN, FACHE, ... of the South announced today that Dr. Robert Menuet, Interventional Cardiologist with Cardiovascular ... Ultrasound Guided Coronary Atherectomy. , This procedure involves the removal of ...
(Date:5/5/2016)... CA (PRWEB) , ... May 05, 2016 , ... TransWipe ... Final Cut Pro X. Drag and drop a TransWipe preset between two video clips ... from smooth corner wipes to colored panels with customizable color and orientation options. TransWipe ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... (LAIs), today announced a development collaboration with the Australian critical medicine company, ... disorders such as schizophrenia. , LAI medicines can offer improved therapeutic benefits over ...
(Date:5/5/2016)... ... May 05, 2016 , ... Einstein Medical is proud to announce ... latest news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, which takes place ... of Cataract and Refractive Surgery and the American Society of Ophthalmic Administrations will be ...
(Date:5/5/2016)... ... ... Friday, May 6 - Sunday, May 8, fifteen elite athletes from Team Semper Fi ... Bike Camp, hosted in conjunction with WTB and Cannondale in Novato, ... share pro tips with the injured veterans as they rip down some of the best ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , May 5, 2016 ... of the  "Europe Systemic Lupus Erythematosus Market ... to their offering.       (Logo: ... latest research Europe Systemic Lupus Erythematosus Market ... comprehensive insights into Systemic Lupus Erythematosus pipeline ...
(Date:5/4/2016)... 2016  It,s time for an upgrade. There are many medical recorders on the ... LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a ... class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... Yissum Research Development Company of the ... had signed an exclusive world-wide licensing and research agreement ... degradation and immunomodulatory drugs for cancer and immune dysfunction, ... first-in-class therapy for hematologic and solid malignancies. Financial terms ... novel technology was developed by Yinon Ben-Neriah , ...
Breaking Medicine Technology: